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Abstract
The transmembrane receptor ‘ROR2’ resembles members of the receptor tyrosine kinase family of signalling receptors in
sequence but its’ signal transduction mechanisms remain enigmatic. This problem has particular importance because
mutations in ROR2 are associated with two human skeletal dysmorphology syndromes, recessive Robinow Syndrome (RS)
and dominant acting Brachydactyly type B (BDB). Here we show, using a constitutive dimerisation approach, that ROR2
exhibits dimerisation-induced tyrosine kinase activity and the ROR2 C-terminal domain, which is deleted in BDB, is required
for recruitment and activation of the non-receptor tyrosine kinase Src. Native ROR2 phosphorylation is induced by the
ligand Wnt5a and is blocked by pharmacological inhibition of Src kinase activity. Eight sites of Src-mediated ROR2
phosphorylation have been identified by mass spectrometry. Activation via tyrosine phosphorylation of ROR2 receptor leads
to its internalisation into Rab5 positive endosomes. These findings show that BDB mutant receptors are defective in kinase
activation as a result of failure to recruit Src.
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Introduction
Human ROR2 is one of two related ROR proteins, identified
by sequence similarity to TRK receptors [1], whose mechanism of
action remains enigmatic. From structural predictions ROR
receptors contain an extra cellular immunoglobulin-like domain;
a cysteine-rich domain (CRD) that resembles the Wnt binding
domain of Frizzled (Fz) receptors; a Kringle motif and single pass
transmembrane domain. The cytoplasmic region contains a
putative kinase domain and a bipartite C-terminal serine/
threonine-rich and proline-rich region [1] containing potential
effector protein docking sites.
Mutations in ROR2 cause two skeletal disorders in humans,
autosomal recessive Robinow Syndrome (RS) and autosomal
dominant Brachydactyly type B (BDB) [2-5]. RS is characterised
by short-limbed dwarfism and costovertebral defects. By contrast
BDB is characterised by shortening of digits, often missing nails
and phalangeal bones, but otherwise normal phenotype. ROR2
mutations causing RS frequently result in truncation of the
receptor in either extra cellular or cytoplasmic regions and are
predicted to be loss of function. ROR2-deficient mice exhibited
severe skeletal defects which are analogous to those of human RS
mutations including dwarfism as well as heart and lung
malformation [6,7]. In contrast, ROR2 mutations causing BDB
result in truncation of the cytoplasmic region, either immediately
before or after the kinase domain and, by virtue of their dominant
acting functions, are predicted to be associated with gain of
function or dominant negative activity.
Despite the significant role ROR2 plays in mammalian
skeletogenesis the molecular mechanism by which it exerts its
biological effects remain elusive. This study aimed to investigate
the role of kinase activation in ROR2 signalling and to determine
the role of the C terminal domain deleted in BDB.
A growing body of evidence implicates members of the Wnt
family of signalling molecules as endogenous ROR2 effectors.
Functional studies in developing xenopus embryos have demon-
strated the role of ROR2 in non-canonical Wnt pathways [8,9]. In
mammals, ROR2 has been shown to bind to a number of
canonical and non-canonical Wnts and mediate non-canonical
Wnt signalling in cultured cells [10–13]. We find that a
constitutively dimerised form of ROR2 exhibits kinase activity
and that Wnt5a-induces activation of Wt ROR2 kinase activity
and internalisation of ROR2 into Rab5 endosomes. We also show
that activation of ROR2 kinase requires the C terminal domain
that is deleted in BDB and that this domain is also required for
recruitment of the non receptor kinase Src. Native ROR2 is a
target for Src mediated phosphorylation and pharmacological
inhibition of Src suppresses ROR2 activation. Collectively these
findings reveal that the BDB mutant ROR2 receptors are defective
in kinase activation via failure to recruit Src.
Results and Discussion
ROR2 Exhibits Intrinsic Kinase Activity
To evaluate the intrinsic kinase activity potential of ROR2, the
cytoplasmic domain of ROR2 was fused to the dimeric Fc portion
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of human IgG to create Fc-ROR2 ‘wild type’ (WT), Fc-ROR2
‘Kinase dead’ and an Fc-ROR2 truncation mutant (Y755X) [14].
Fig. 1A shows a schematic detailing these constructs as well as the
original full length, myc-tagged ROR2 constructs. Following
expression in T/C28a2 human chondrocytes, robust Fc-ROR2
WT phosphorylation was detected in contrast with a markedly
reduced phosphorylation of Fc-ROR2 KD. This suggests that,
despite divergence from the RTK consensus sequence [15],
ROR2 has intrinsic kinase activity which is elicited upon
dimerisation (Fig. 1B, upper panel). This confirmed the recent
reports that ROR2 is phosphorylated upon homo-dimerisation
[16]. It was noted in these experiments that, although markedly
reduced compared to WT, residual receptor phosphorylation was
observed in cells expressing Fc-ROR2 KD, raising the possibility
there may be other tyrosine kinases or co-receptors involved in
ROR2 receptor phosphorylation, although the presence of
residual endogenous kinase activity in the mutant cannot be
rigorously excluded.
A truncated receptor variant, Fc-ROR2 Y755X lacking the C-
terminal region of ROR2 and emulating the BDB mutant form of
ROR2, was also expressed in chondrocytes and evaluated for
tyrosine phosphorylation. Fc-ROR2 Y755X exhibited markedly
reduced levels of tyrosine phosphorylation compared to Fc-ROR2
WT (despite equivalent levels of expression, Fig. 1B, lower panel)
resembling that observed by mutation of the ATP binding pocket
in Fc-ROR2 KD. This suggests either the majority of tyrosine
residues that are phosphorylated in the Fc-ROR2 WT protein are
located C-terminal to Y755 or the reduced phosphorylation
observed in Fc-ROR2 Y755X is due to lack of binding sites for
non-receptor tyrosine kinases that may contribute to ROR2
phosphorylation. In either case, this result highlights the essential
role of ROR2 C-terminal for its full activation.
Wnt5a activates Tyrosine Phosphorylation of ROR2
As discussed above, members of the Wnt family of ligands have
been implicated in ROR2 signalling. Having established that
ROR2 could exhibit intrinsic kinase activity (albeit of an unusual
kind) we were interested in discovering if Wnt ligands could elicit
activation of the kinase activity of native ROR2 receptors.
Chondrocytes transfected with full length myc-tagged ROR2
(ROR2-myc WT) were stimulated with either BSA carrier or
Wnt5a for 5, 30 or 60 min. The receptor was immunoprecipitated
and receptor phosphorylation was detected by phosphotyrosine
immunoblotting (Fig. 2A, upper panel). A marked increase in
receptor tyrosine phosphorylation after 30 min of Wnt5a stimu-
lation was detected compared to carrier stimulated controls. These
findings show that Wnt5a ligand elicits tyrosine phosphorylation of
native ROR2, confirming that Wnt5a is, directly or indirectly, a
bona fide activator of ROR2 signalling, acting via stimulation of
intrinsic tyrosine kinase activity.
Src Phosphorylates ROR2
The foregoing data are consistent with Wnt5a-mediated
dimerisation of ROR2 being a primary mechanism of receptor
activation but do not eliminate the engagement of non-receptor
tyrosine kinases or co-receptors in this process. This possibility is
strengthened by the presence of residual C-terminal phosphory-
lation in the Fc-ROR2 KD construct. We accordingly sought
candidate non-receptor tyrosine kinases that could employ
dimerised ROR2 as a substrate.
A notable feature of the anti-phosphotyrosine blots of
immunoprecipitated native ROR2 stimulated with Wnt5a was a
tyrosine phosphorylated protein of ,60 KDa (data not shown).
Src family kinases have been directly implicated in signalling from
a number of RTKs [17] and therefore the possibility that this
unknown protein was a Src family kinase was further investigated.
Immunoprecipitated ROR2 was probed for active Src (using anti-
phospho-Src Y416) and an immunoreactive protein, at the
predicted MW of Src, was recruited to the receptor upon 30 min
of Wnt 5a stimulation (Fig. 2B, upper panel). This result indicates
that recruitment and activation of Src kinase is a consequence of
Wnt5a stimulation of ROR2. It should be noted that the C-
Figure 1. Fc-ROR2 WT is tyrosine phosphorylated. A) A schematic diagram of the full length ROR2 and Fc-ROR2 chimeras used in this study.
‘Kinase dead’ (KD) mutants were constructed by mutating three Lysine residues within the ATP binding pocket to Argenine. B) Fc fusion chimeras of
the intracellular domains from ROR2 WT, ROR2 KD, ROR2 Y755X and, as a control, the Fc-transmembrane domain of FGFR1 fusion were expressed in
chondrocytes. The chimeric receptors were immunoprecipitated using Protein-A-sepharose (IP-PA) and analysed by Western blotting following 10%
SDS-PAGE. Receptor phosphorylation was detected by a cocktail of phosphotyrosine antibodies (4G10/pY20; WB-pY, upper panel). The membrane
was stripped and reprobed with anti-IgG1 antibody to compare receptor expression levels (WB-Fc, lower panel).
doi:10.1371/journal.pone.0001873.g001
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terminal region of ROR2, deleted in BDB, contains both putative
consensus Src SH2 domain (Y786XXP, Y873VTT) [18] and SH3
(R809PMVPPP) domain [19] recognition sites.
Chondrocytes expressing ROR2-myc constructs exhibited
slightly elevated Src activity when compared to non-ROR2
expressing cells and Src activity was dramatically increased in
ROR2 expressing cells upon Wnt5a stimulation (Fig. 3). Active Src
co-localised with ROR2-myc WT in both cell surface and
intracellular locations indicative of a role in intracellular trafficking
(Fig. 3A). We also noted in these experiments that ROR2-myc
WT transfected cells exhibited extensive filopodia as reported
previously [12]. ROR2-myc KD, similar to WT, co-localised with
active Src (Fig. 3B) contrasting with the expression of ROR2-myc
L747X, which not only resulted in lower Src activation even after
Wnt5a stimulation, compared to either ROR2-myc WT or KD,
but also exhibited far less co-localisation (Fig. 3C).
We next sought to identify the ROR2 cytoplasmic domain(s)
that are essential for Src kinase binding. Full length ROR2-myc
WT, KD, P860X and L747X were co-expressed in chondrocytes
with either a constitutively active Src Y527F (Src A) or a kinase
dead Src K295M/Y527F (Src MF). ROR2-myc WT, KD, and
P860X receptors were tyrosine phosphorylated in a ligand-
independent manner when co-expressed with Src Y527F (Fig. 4).
Phosphorylation of L747X mutant was almost ablated compared to
the WT receptor, indicating that the C-terminal proline-rich and/
or the first serine/threonine-rich regions are essential for Src
binding. No receptor phosphorylation was observed when Src MF
was co-expressed with any of the ROR2-myc constructs.
Collectively, results in figures 2 and 3 establish that Wnt5a
activation of ROR2 results in Src kinase activation and that
activated Src kinase is able to phosphorylate ROR2 upon tyrosine
residues. Thus Wnt5a stimulation results in two pathways of
ROR2 phosphorylation: one via receptor dimerisation and a
second via recruitment of Src. The consequence of these combined
actions is prominent phosphorylation of the receptor on tyrosine
residues.
We next sought to identify the substrates for Src-mediated
phosphorylation in ROR2. Full length ROR2-myc WT was co-
expressed with Src A, immunoprecipitated and tryptic peptides
subjected to CID MS/MS (Supplementary Fig. S1 and Supple-
mentary Tables S1 and S2). Eight Src-dependent ROR2
phosphorylation sites were identified by mass spectrometry with
48.6% sequence coverage including the dual tyrosines Y645/Y646
in the predicted activation loop of ROR2 and Y873 in the BDB
domain.
Wnt5a induces ROR2 internalisation into Rab5 positive
vesicles
Activation of RTK kinase activity results in internalisation of
activated receptor complexes resulting in both signal propagation
and degradation. Receptors internalised via kinase-dependent
pathways are initially targeted into early endosomes before sorting
for either recycling or degradation [20]. The vesicular sorting Rab
5 GTPase is localised to early endosomes, regulates plasma
membrane-endosome fusion [21] and, at least for some RTKs
[22] influences signalling outcomes. If Wnt5a activation of ROR2
phosphorylation yields a productive signalling response it is
predicted that internalisation of ROR2 into Rab5 positive vesicles
would occur. ROR2-myc WT or KD transfected cells were
stimulated with either 0.1% BSA carrier or Wnt5a and the sub-
cellular localisation of ROR2 and Rab5A were examined by
immunofluorescence. Clearly ROR2-myc WT co-localisation with
Rab5A was increased after 5 min but not after 30 min (Fig. 5A,
upper and middle panels, respectively) of Wnt5a stimulation.
These findings show that activation of ROR2 phosphorylation via
Wnt5a results in rapid receptor internalisation into Rab5 positive
sorting endosomes. It also provides a functional readout for ROR2
signalling although, given ignorance of the downstream signalling
Figure 2. ROR2 receptor exhibits increased tyrosine phosphorylation and Src association upon Wnt5a stimulation. A) Chondrocytes
were either transfected with pcDNA3.1 (V, control) or pcDNA3.1 containing the myc-tagged, wild type, ROR2 construct (ROR2-myc WT). Following
1 hr of serum starvation in KHB, cells were either stimulated with 0.1% BSA carrier (C) or Wnt5a (1.6 mg/ml) for 5, 30 or 60 min. Control vector-
transfected cells (V) were not stimulated. The receptor was immunoprecipitated using anti-myc antibody (IP-myc) and analysed by SDS-PAGE and
subsequent Western blotting. The membrane was probed with an anti-phosphotyrosine cocktail (WB-pY), followed by stripping and re-probing with
anti-myc antibody (WB-myc). The fold-increase of ROR2 receptor phosphorylation was determined by normalizing Wnt5a-induced phosphorylation to
carrier-induced phosphorylation (mean6s.e.m., n = 3, lower panel). B) Chondrocytes expressing ROR2-myc WT were stimulated with either 0.1% BSA
(C) or Wnt5a (1.6 mg/ml) for 30 min. The receptor was immunoprecipitated using anti-myc antibody (IP-myc) and probed with a phospho-Src
antibody (WB-pSrc-Y416) to detect activated Src. The membrane was stripped and reprobed with anti-c-Src (WB-cSrc) and anti-myc (WB-myc).
doi:10.1371/journal.pone.0001873.g002
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pathways employed by ROR2, this could indicate either
attenuation or sustained signalling. Given the prominent role for
Src in ROR2 kinase activation described above we evaluated the
role of Src kinase activity in the Wnt-induced localisation into
Rab5 endosomes. ROR2-myc WT transfected chondrocytes were
incubated with a Src family kinase inhibitor (SU6656) prior to
stimulation with 0.1% BSA carrier or Wnt5a for 5 min (Fig. 5A,
lower panel) and the effect on sub-cellular localisation of ROR2
was detected by immunofluorescence. ROR2 showed little co-
localisation with Rab5 when Src was pharmacologically inhibited.
Collectively, these results show that Src activity is a requirement
for ROR2 trafficking into the Rab5 positive endosomal compart-
ment following activation by Wnt5a. Interestingly, despite the
‘latent’ phosphorylation of Fc-ROR2 KD (Fig. 1B), only marginal
co-localisation with Rab5A was observed after 5 min of Wnt5a
stimulation (Fig. 5B, upper panel) and no co-localisation after
either 30 min or 5 min following treatment with SU6656 (Fig. 5B,
middle and lower panels, respectively). No co-localisation was ever
observed when cells were stimulated with 0.1% BSA carrier.
This leads to an ‘‘ignition trigger’’ model of ROR2 activation
whereby low level intrinsic ROR2 kinase activity is sufficient to
recruit and activate Src which amplifies ROR2 receptor
phosphorylation to the full active state. This jointly explains the
apparently weak kinase activity, the requirement for an intact ATP
binding site, the requirement of functional Src kinase and the key
role of the BDB domain in ROR2 function. Our findings indicate
that ROR2 represents a second non-canonical pathway for Wnt
signalling which is an unorthodox example of classical RTK
mediated signalling which proceeds by ligand-mediated receptor
homo-dimerisation followed by tyrosine phosphorylation of
receptor substrate residues and propagation of the signal. In
support of this model we show that dimerisation is sufficient to
induce ROR2 activation and that Wnt5a induces ROR2
phosphorylation. A secondary role for co-receptors in ROR2
Figure 3. Wnt5a-induced association of activated Src and the ROR2 receptor. Chondrocytes were transfected with; A) ROR2-myc WT, B)
ROR2-myc KD or C) ROR2-myc L747X and serum-starved for 1 hr in KHB prior to stimulation with either 0.1% BSA carrier or Wnt5a (1 mg/ml) plus
heparin (10 mg/ml) for 30 min. The cells were fixed and stained with anti-myc, anti-phospho-Src (Y416) and Hoechst.
doi:10.1371/journal.pone.0001873.g003
Src Required for ROR2 Activity
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signalling [13,23] cannot however be ruled out on the basis of the
evidence presented here but these would of necessity involve
pathways that do not involve either tyrosine kinase activity or BDB
domain of ROR2.
Biological Implications
We now turn to the significance of these findings for
understanding the pathology of human BDB mutations in
ROR2. Our results show that the region deleted in BDB mutants
is required for efficient ROR2 phosphorylation. This region also
contains potential binding sites for Src and target sites for
phosphorylation and recruitment of potential downstream effec-
tors. Thus deletion of this region, as found in BDB mutants, yields
a receptor which is competent to bind Wnt ligand but unable to
produce a productive tyrosine phosphorylation signalling response.
In classical RTK signalling receptors this type of mutant would,
depending upon gene dosage, be predicted to exhibit dominant
negative properties which diminish the signalling functions of
endogenous native receptors in the presence of ligand. This would
suggest that heterozygous BDB mutations (if expressed at
appropriate levels) would resemble loss of function homozygous
RS mutants. This is clearly not the case as the phenotypes of the
two syndromes are quite distinct. The alternative explanation is
that BDB mutations represent a gain of function phenotype
whereby ablation of the ROR2 tyrosine kinase pathway results in
the activation (or relief of repression) of signalling pathways in the
limb which leads to digit truncation [24]. Candidate pathways
would include those repressed by Src kinase activity and limited to
digit primordia and not other regions of ROR2 expression [24].
Methods
Cell Culture and Transfection
T/C-28a2 human chondrocytes (a generous gift of Dr.
Goldring, Saint Louis University, USA) were cultured at 37uC,
5% CO2 for up to six months in a mixture of Dulbecco’s modified
Eagle medium and Ham’s F12 (1:1, v/v) supplemented with
2 mM glutamine (Invitrogen), 0.1 mg/mL streptomycin, 0.2 U/
mL penicillin, 4.5 g/L glucose (Sigma) and 10% fetal calf serum
(v/v) (Labtech International). Cells were transfected with Lipo-
fectamine 2000 (Invitrogen) according to manufacturer’s instruc-
tion except using only half the amount of plasmid DNA and
Lipofectamine 2000 reagent recommended.
Reagents and Antibodies
Recombinant murine Wnt5a was obtained from R&D Systems.
SU6656 Src inhibitor (used at 24 mM) was purchased from
CALBIOCHEM. Primary antibodies used in this study were:
mouse anti-IgG-Fc-HRP conjugate and mouse anti-IgG (Pierce);
mouse anti-myc; rabbit anti-phospho-Src Y416 (Cell Signalling);
the anti-phosphotyrosine cocktail used in western blotting
comprised mouse anti-phospho-tyrosine clone 4G10TM (Upstate)
and clone pY20 (ICN Biomedicals, Inc.); rabbit anti-Rab5A and
rabbit anti-cSrc (Santa Cruz). The secondary antibodies were anti-
mouse- and anti-rabbit-IgG Horseradish Peroxidase conjugates
(Amersham). The secondary antibodies for immunofluorescence
studies were anti-mouse-Alexa 546 (Molecular Probe) and anti-
rabbit-FITC (DAKO).
cDNA Constructs
The pcDNA3.1 mouse myc-tagged ROR2 was a generous gift
of Dr. Minami (Kobe University, Japan). The chicken constitu-
tively active Src (Src Y527F, Src A) and kinase dead Src (Src Y527F,
K295M, Src MF) in pBabe Puro were generous gifts of Dr. Frame
(The Beatson Institute for Cancer Research, UK).
ROR2 L747X was amplified using a primer pair that intro-
duced a XhoI restriction site at the point of truncation: XF
(59-AAGGAAAAAAGCGGCCCTCGAGGTCGACCCACGCG-
TCCG-39) and L747XR (59-ATAATCCTCGAGGAGCCG-
GCTGTGGATGTC-39). The amplified product was digested with
XhoI restriction enzyme and sub-cloned into pcDNA3.1-myc.
Similarly, the ROR2 P860X mutant was constructed using XF and
P860XR (59-CAGTTCCTCGAGCGGCTTGGGGACCATCTG-39)
primers.
The Fc-ROR2 WT in pEFBOS was constructed by inserting
the transmembrane, cytoplasmic and the 39 flanking region of
ROR2 (IMAGE clone 2231989; a generous gift of Dr. Wilkie,
Oxford University, UK), into ss-Fc-IRES-Tpz-pEFBOS vector.
The Fc-ROR2 Y755X truncation mutant was generated by overlap
extension mutagenesis. Two PCR reactions using two mutagenic
primers 6Lstop (59-CTTTCCAATTAAAACAGCTCGG-39) and
6Rstop (59-CCGAGCTGTTTTAATTGGAAAG-39) that intro-
duced a stop codon at Y755 and a silent Mse1 restriction site for
selection and two outside primers (5R: 59-GATCTGCACCGGG-
TAGAAGTTG-39 & 5L: 59-CAACCAGGATGTGGTGGA-
GATG-39). The kinase dead mutations (K507,510,512R) of both full
length and Fc-conjugated ROR2 were generated using Quick-
ChangeH II XL Site-Directed Mutagenesis Kit (Stratagene)
according to manufacturer instructions using primers 3K-3RF
(59-GGCCGTGGCCATCAGGACGCTGAGAGACAGGGCT-
GAGGGGCCCC-39), and the second primer that was the reverse
complementary sequence to 3K-3RF.
Wnt5a stimulation, Immunoprecipitation and Western
Blotting
Following serum starvation in Krebs Hepes Buffer (KHB)
chondrocytes were stimulated with either carrier control (0.1%
BSA in PBS (w/v)) or Wnt5a (1.0-1.6 mg/mL). The reaction was
stopped by adding 10x volume cold PBS. Cells were lysed in lysis
buffer (150 mM NaCl; 10 mM Tris-HCl; 1 mM EGTA; 1 mM
EDTA; 1% NP-40 (v/v); 1 mM Na3VO4; 50 mM NaF and 1
tablet of complete protease inhibitor cocktail (Roche) per 10 ml of
Figure 4. ROR2 receptor is a substrate for Src. Chondrocytes were
co-transfected with myc-tagged ROR2 WT, ROR2 KD and myc-tagged
deletion mutants ROR2 P860X and ROR2 L747X and either vector alone
(V), constitutively active Src (Src A) or inactive Src (Src MF). Lanes 5 and
6 are controls for Src A and Src MF, respectively. The receptor constructs
were immunoprecipitated with anti-myc (IP-myc) and probed with anti-
phosphotyrosine antibodies (WB-pY, upper panel) then stripped and
reprobed with anti-myc (loading control, WB-myc). Src A and MF
expression was confirmed on whole cell lysate prior to immunoprecip-
itation using anti-chicken Src antibody (WB-EC10, lower panel).
doi:10.1371/journal.pone.0001873.g004
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buffer, PH 7.5). For ROR2-myc immunoprecipitation, 200–
500 mg whole cell lysate was incubated with 0.5 mg anti-myc
antibody for 1 hr at 4uC followed by incubating the mixture with
30 ml of a 50% protein A-sepharose slurry (Amersham Biosciences)
for 1 hr hour at 4uC. The immunoprecipitates were washed
excessively and boiled in 26 SDS sample buffer (100 mM Tris-
HCl; 10% glycerol (v/v); 2% SDS (w/v); 0.1% bromophenol blue
(w/v); 200 mM DTT; pH 6.8) for 5 min at 95uC prior to running
on SDS PAGE.
Gels were transferred to PVDF membrane (Millipore) and
blocked in TBS-T containing 5% bovine serum albumin (BSA, w/
v). Primary antibodies (in TBS-T/5% BSA) were incubated with
the membrane for 1 hr at room temperature or 4uC overnight.
The membrane was washed (3615 min) in TBS-T and subse-
quently probed with the conjugated secondary antibody (in TBS-
T/1% BSA) for 45 min at room temperature. The membrane was
washed (5610 min) with TBS-T, before membranes were exposed
to ECL reagents (Pierce) for visualization of immunoreactive
proteins.
Immunofluorescence
T/C-28a2 chondrocytes were grown on acid scratched glass
cover slips. Following Wnt5a stimulation, cells were washed in
cold PBS and fixed in 4% paraformaldehyde (w/v) for 10 min at
room temperature. Cells were then washed 3 times in PBS and
permeabilised in 0.2% triton X-100 (v/v)/ 0.5% BSA (w/v) for 3-
Figure 5. ROR2 is targeted into Rab5A-positive endosomes upon Wnt5a stimulation. A) ROR2-myc WT and B) ROR2-myc KD transfected
chondrocytes were serum-starved in KHB for1 hr. Cells were stimulated with either 0.1% BSA carrier or Wnt5a (1 ug/ml) plus heparin (10 mg/ml) for
5 min (upper panels), 30 min (middle panels) or 5 min in the presence of 24 mM SU6656 (lower panels). The cells were fixed and subsequently stained
with anti-myc and anti-Rab5A antibodies.
doi:10.1371/journal.pone.0001873.g005
Src Required for ROR2 Activity
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5 min, followed by washing with PBS. Non-specific binding sites
were then blocked with 4% BSA/TBST (w/v) for 10 min. The
cover slips were incubated in a cocktail of primary antibodies (1:
100 in 4% BSA/TBST (w/v)) for one hour, followed by
incubation in each secondary antibody (1: 100 in 4% BSA/TBST
(w/v)) separately with PBS washes between each staining. The
cover slips were mounted onto glass slides using Mowiol and
viewed by direct immunofluorescence using the Leica inverted
confocal microscope (DM IRE2). Image J was used to analyse the
images. Each experiment was repeated at least three times. 50 cells
were counted for quantification purposes.
Mass Spectrometric Identification of Sites of
Phosphorylation
ROR2-myc was co-expressed with active Src (Src A) or inactive
Src (Src MF) for 24 h in T/C 28a2 chondrocytes. ROR2-myc was
immunoprecipitated using anti-myc antibody and was separated
by SDS-PAGE. Following Coomassie staining, the ROR2-myc
band was excised. Cysteines were reduced (10 mM dithiothreitol)
and alkylated (50 mM iodoacetamide) prior to overnight in-gel
trypsin digestion (12.5 ng/ml; Trypsin Gold; Promega, Madison,
WI, USA) in 25 mM ammonium bicarbonate.
Phosphopeptides were enriched from the resulting mixture by
TiO2 affinity chromatography according to Larsen et al. (25), with
minor modifications. Peptides were loaded onto TiO2 micro-
columns in 2% TFA. Columns were washed with 100 mg/ml
DHB, 80% MeCN, 2% TFA, then with the same buffer omitting
DHB. Peptides were eluted in a two-step procedure with 50 mM
Na2HPO4 followed by dilute NH4OH solution. Eluates were
desalted using ZipTips (Millipore). The resulting peptide mixtures
(eluates and un-bound fraction) were analysed by liquid chroma-
tography mass spectrometry (LC-MS/MS).
On-line liquid chromatography was performed by use of a
Micro AS autosampler and Surveyor MS pump (Thermo
Electron, Bremen, Germany). Peptides were loaded onto a
75 mm (internal diameter) Integrafrit (New Objective, USA) C8
resolving column (length 10 cm) and separated over a 40 minute
gradient from 0% to 40% acetonitrile (Baker, Holland). Peptides
eluted directly (,350 nL/min) via a Triversa nanospray source
(Advion Biosciences, NY, USA) into a 7 Tesla LTQ FT mass
spectrometer (Thermo Electron). The mass spectrometer alternat-
ed between a full FT-MS scan (m/z 395-1600), subsequent CID
MS/MS scans of the five most abundant ions, and, if a neutral loss
of 98 Da from the precursor ion was observed in the CID mass
spectrum, an MS3 scan of the neutral loss ion. Survey scans were
acquired in the ICR cell with a resolution of 100,000 at m/z 400.
Precursor ions were isolated and subjected to CID in the linear ion
trap. Isolation width was 3 Th. Only multiply-charged precursor
ions were selected MS/MS. CID was performed with helium gas
at normalized collision energy of 35%. Precursor ions were
activated for 30 ms. Data acquisition was controlled by Xcalibur
2.0 software. Data were searched against the Swissprot database
using the SEQUEST (Thermo Electron) and Mascot algorithms
(Matrix Sciences, UK). Phosphorylation site localisation was
assessed using the A-score algorithm (26), with manual validation.
Supporting Information
Figure S1 The annotated mass spectra of phosphorylation sites
in the mouse ROR2 cytoplasmic regions. Eight Src-dependent
phosphopeptides were identified by mass spectrometry.
Found at: doi:10.1371/journal.pone.0001873.s001 (0.50 MB TIF)
Table S1
Found at: doi:10.1371/journal.pone.0001873.s002 (0.07 MB
DOC)
Table S2
Found at: doi:10.1371/journal.pone.0001873.s003 (0.06 MB
DOC)
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